Impact of transcranial direct current stimulation on sustained attention in breast cancer survivors: Evidence for feasibility, tolerability, and initial efficacy.
Breast cancer
Cancer-related cognitive dysfunction
Sustained attention
tDCS
Journal
Brain stimulation
ISSN: 1876-4754
Titre abrégé: Brain Stimul
Pays: United States
ID NLM: 101465726
Informations de publication
Date de publication:
Historique:
received:
19
10
2019
revised:
26
02
2020
accepted:
19
04
2020
pubmed:
1
5
2020
medline:
15
12
2020
entrez:
1
5
2020
Statut:
ppublish
Résumé
A significant subset of breast cancer survivors experience cognitive difficulties in attention and memory, which persist for years following treatment. Transcranial direct current stimulation (tDCS) has been shown to be effective in improving working memory, attention, processing speed, and other cognitive functions in both healthy and clinical populations. To date, no studies have examined tDCS for rehabilitation of cancer-related cognitive dysfunction. We aimed to provide preliminary evidence for feasibility, tolerability, acceptability, and efficacy of tDCS in improving performance on a measure of sustained attention. In a within-subjects design, 16 breast cancer survivors underwent 2 consecutive days of active tDCS over the prefrontal cortex, and 2 days of sham tDCS, counterbalanced for order of stimulation condition, while performing a continuous performance test. Stimulation was feasible and tolerable, with 89% of participants completing all sessions, and none reporting more than mild to moderate discomfort. Analyses of efficacy showed that during active stimulation, participants had significantly lower standard errors of reaction times overall, indicating better sustained attention ability, as compared to sham stimulation (p < 0.05). Furthermore, the effect of stimulation on standard errors of reaction times differed by inter-stimulus interval (ISI): for 1 and 2 s ISIs, there was no significant difference in performance between sham and active tDCS conditions, but for 4 s ISIs, stimulation improved variability in response times relative to sham (p < 0.05). Results suggest that tDCS is feasible, tolerable, and may be an effective intervention to improve sustained attention difficulties in survivors with cancer-related cognitive dysfunction.
Sections du résumé
BACKGROUND
A significant subset of breast cancer survivors experience cognitive difficulties in attention and memory, which persist for years following treatment. Transcranial direct current stimulation (tDCS) has been shown to be effective in improving working memory, attention, processing speed, and other cognitive functions in both healthy and clinical populations. To date, no studies have examined tDCS for rehabilitation of cancer-related cognitive dysfunction.
OBJECTIVE/HYPOTHESIS
We aimed to provide preliminary evidence for feasibility, tolerability, acceptability, and efficacy of tDCS in improving performance on a measure of sustained attention.
METHODS
In a within-subjects design, 16 breast cancer survivors underwent 2 consecutive days of active tDCS over the prefrontal cortex, and 2 days of sham tDCS, counterbalanced for order of stimulation condition, while performing a continuous performance test.
RESULTS
Stimulation was feasible and tolerable, with 89% of participants completing all sessions, and none reporting more than mild to moderate discomfort. Analyses of efficacy showed that during active stimulation, participants had significantly lower standard errors of reaction times overall, indicating better sustained attention ability, as compared to sham stimulation (p < 0.05). Furthermore, the effect of stimulation on standard errors of reaction times differed by inter-stimulus interval (ISI): for 1 and 2 s ISIs, there was no significant difference in performance between sham and active tDCS conditions, but for 4 s ISIs, stimulation improved variability in response times relative to sham (p < 0.05).
CONCLUSIONS
Results suggest that tDCS is feasible, tolerable, and may be an effective intervention to improve sustained attention difficulties in survivors with cancer-related cognitive dysfunction.
Identifiants
pubmed: 32353419
pii: S1935-861X(20)30092-9
doi: 10.1016/j.brs.2020.04.013
pmc: PMC7446233
mid: NIHMS1617554
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1108-1116Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009461
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002384
Pays : United States
Informations de copyright
Copyright © 2020. Published by Elsevier Inc.
Références
J Clin Oncol. 2016 Feb 20;34(6):611-35
pubmed: 26644543
Brain Stimul. 2016 Jul-Aug;9(4):501-17
pubmed: 27160468
Cancer Nurs. 2007 Mar-Apr;30(2):101-11
pubmed: 17413775
Neuropsychologia. 2018 Oct;119:524-534
pubmed: 30227147
J Clin Oncol. 2012 Jul 10;30(20):2500-8
pubmed: 22665542
Eur J Oncol Nurs. 2013 Apr;17(2):236-41
pubmed: 22901546
Breast Cancer Res Treat. 2010 Oct;123(3):819-28
pubmed: 20690040
J Int Neuropsychol Soc. 2014 Apr;20(4):380-90
pubmed: 24621519
J Pain Symptom Manage. 2014 Jan;47(1):35-44
pubmed: 23707383
J Clin Oncol. 2012 Jan 20;30(3):274-81
pubmed: 22184379
Psychooncology. 2013 Oct;22(10):2354-63
pubmed: 23657969
Neuromodulation. 2016 Dec;19(8):824-831
pubmed: 27089545
Hum Brain Mapp. 2011 Aug;32(8):1206-19
pubmed: 20669165
J Int Neuropsychol Soc. 2016 May;22(5):530-9
pubmed: 26960672
Clin Cancer Res. 2009 Nov 1;15(21):6665-73
pubmed: 19843664
Breast Cancer Res Treat. 2005 Nov;94(1):53-61
pubmed: 16175317
Contemp Clin Trials. 2015 Nov;45(Pt B):371-376
pubmed: 26427563
Semin Oncol Nurs. 2013 Nov;29(4):280-7
pubmed: 24183159
Neuropsychologia. 2004;42(14):1910-6
pubmed: 15381021
Behav Brain Res. 2016 Dec 15;315:10-22
pubmed: 27478140
Clin Breast Cancer. 2013 Aug;13(4):299-306
pubmed: 23647804
Nat Rev Neurosci. 2002 Mar;3(3):201-15
pubmed: 11994752
Oncol Nurs Forum. 2012 Jan;39(1):E31-40
pubmed: 22201666
Front Psychol. 2014 Jul 25;5:800
pubmed: 25120513
Br J Cancer. 2006 Mar 27;94(6):828-34
pubmed: 16523200
Psychooncology. 2006 Oct;15(10):921-30
pubmed: 16477674
J Clin Oncol. 2014 Jul 1;32(19):2031-8
pubmed: 24868029
Trends Neurosci. 2006 Aug;29(8):474-80
pubmed: 16820224
J Clin Oncol. 2012 Apr 20;30(12):1335-42
pubmed: 22430268
Front Cell Neurosci. 2015 May 12;9:181
pubmed: 26029052
Am J Psychiatry. 1999 May;156(5):675-82
pubmed: 10327898
J Cancer Surviv. 2016 Jun;10(3):437-48
pubmed: 26586494
Front Psychiatry. 2012 Oct 22;3:91
pubmed: 23097644
Front Syst Neurosci. 2014 Feb 24;8:25
pubmed: 24605090
J Cancer Surviv. 2013 Jun;7(2):262-73
pubmed: 23552976
J Clin Oncol. 2017 Jan 10;35(2):217-225
pubmed: 28056205
Psychooncology. 2015 Aug;24(8):958-66
pubmed: 25336068
Psychooncology. 2007 Aug;16(8):772-7
pubmed: 17152119
Brain Stimul. 2012 Jul;5(3):223-230
pubmed: 21840288
Brain Imaging Behav. 2013 Dec;7(4):543-53
pubmed: 23955490
Psychooncology. 2009 Jul;18(7):775-82
pubmed: 19061196
Depress Anxiety. 2006;23(8):482-4
pubmed: 16845648
Schizophr Res. 2015 Oct;168(1-2):260-6
pubmed: 26190299
Arthritis Rheum. 2006 Dec;54(12):3988-98
pubmed: 17133529
J Natl Cancer Inst. 2006 Dec 6;98(23):1742-5
pubmed: 17148777
Breast Cancer Res Treat. 2013 Jan;137(2):493-502
pubmed: 23263697
J Occup Environ Med. 2010 Feb;52(2):219-27
pubmed: 20134340
Eur J Oncol Nurs. 2007 Feb;11(1):6-15
pubmed: 16844416
Cancer. 1999 Feb 1;85(3):640-50
pubmed: 10091737
Neuroimage Clin. 2015 Feb 20;7:547-54
pubmed: 25844311
Neuroscience. 2008 Nov 11;157(1):95-104
pubmed: 18835334
Brain Behav Immun. 2013 Mar;30 Suppl:S117-25
pubmed: 22613170
Neuroscientist. 2011 Feb;17(1):37-53
pubmed: 21343407
J Clin Oncol. 2007 Sep 1;25(25):3866-70
pubmed: 17761972
Cancer. 2007 May 1;109(9):1905-13
pubmed: 17351951
Support Care Cancer. 2008 Jun;16(6):577-83
pubmed: 17972110
J Cancer Surviv. 2009 Dec;3(4):223-32
pubmed: 19760150
Cancer. 2007 Jan 1;109(1):146-56
pubmed: 17131349
Psychooncology. 2015 May;24(5):548-55
pubmed: 25044928
J Oncol Pract. 2007 Mar;3(2):54-9
pubmed: 20859374
Brain Stimul. 2014 Sep-Oct;7(5):767-8
pubmed: 25085269
Hum Brain Mapp. 2014 Mar;35(3):889-99
pubmed: 23281152
Support Care Cancer. 2012 Jun;20(6):1235-42
pubmed: 21688163
Oncol Nurs Forum. 2014 Jan 1;41(1):67-76
pubmed: 24368240
Arch Neurol. 2011 Nov;68(11):1447-53
pubmed: 22084128
Psychooncology. 2006 Oct;15(10):891-7
pubmed: 16374892
Front Psychol. 2014 Apr 07;5:280
pubmed: 24778623
J Am Geriatr Soc. 2006 Jun;54(6):925-31
pubmed: 16776787
Breast Cancer Res Treat. 2006 Aug;98(3):343-8
pubmed: 16541322
J Clin Neurosci. 2018 Nov;57:51-57
pubmed: 30193898
Life Sci. 2013 Oct 17;93(17):617-22
pubmed: 24012579
Clin Neurophysiol. 2008 Mar;119(3):533-541
pubmed: 18164658
J Cancer Surviv. 2016 Jun;10(3):593-9
pubmed: 26658913
Neuroimage Clin. 2018 Jul 12;20:110-118
pubmed: 30094161
Arch Clin Neuropsychol. 2016 Jun;31(4):365-77
pubmed: 27193366
J Clin Nurs. 2010 May;19(9-10):1362-70
pubmed: 20500346
Hum Brain Mapp. 2011 Mar;32(3):480-93
pubmed: 20725909
Psychooncology. 2013 May;22(5):1043-9
pubmed: 22570263
J Clin Exp Neuropsychol. 2008 Oct;30(7):741-8
pubmed: 18608653
Assessment. 2008 Jun;15(2):123-31
pubmed: 18187398
Neuroimage. 2011 Feb 14;54(4):3040-7
pubmed: 20946963
Cancer. 2009 Jun 15;115(12):2605-16
pubmed: 19309747
PLoS One. 2008 Mar 19;3(3):e1794
pubmed: 18350136
J Clin Oncol. 2002 Jan 15;20(2):485-93
pubmed: 11786578
J Pain Symptom Manage. 2009 Nov;38(5):650-62
pubmed: 19896571